Apr. 5 at 1:40 PM
$RIGL
I think once the CNS drug was returned by Lily, the chance of a buyout was practically gone. The RA drug already has an agreement in place (all the way through), so lily has no incentive to buy out the company for that drug. The approved drugs have value but doesn’t make them a buyout target. They have an MDS drug that is years away and faces fierce competition. What makes this co a Target of a potential buy-out?
I think the value of this company is in its totality.
they have a profitable company in place already, some of the same drugs are in the clinic for other indications, have a puppet drugs in the pipeline, and looking to buy other assets or collaborate with another company.
Remember they now have experience with product launch, sales and customer care service, so they will be attractive to small companies looking to launch products. The last big hire was brought in for that purpose.
All of that makes this a very investable company in my opinion. GLTA!
